Background: Neuroendocrine neoplasms (NENs) are increasing in incidence globally. Previous analysis of the UK cancer database (National Cancer Registration and Analysis Service (NCRAS)) showed a notable female survival advantage in most tumour sites. This study aims to compare NCRAS to the Surveillance, Epidemiology, and End Results Program (SEER) to validate these results using the same statistical methods. Methods: A total of 14,834 and 108,399 patients with NENs were extracted from NCRAS and SEER, respectively. Sixty-months survival for both males and females for each anatomical site of NENs were calculated using restricted mean survival time (RMST) and Kaplan–Meier Survival estimates. The sixty-month RMST female survival advantage (FSA) was calculated. Results: FSA was similar in NCRAS and SEER. The highest FSA occurred in lung and stomach NENs. Conclusions: The data from SEER confirm the findings published by NCRAS. Female survival advantage remains unexplained.
背景：神经内分泌肿瘤在全球范围内的发病率呈上升趋势。先前对英国癌症数据库（国家癌症登记与分析服务）的分析显示，在大多数肿瘤部位中，女性患者存在显著的生存优势。本研究旨在通过相同的统计方法，将NCRAS数据与美国监测、流行病学和最终结果计划数据库进行比较，以验证上述结果。方法：分别从NCRAS和SEER数据库中提取14,834例和108,399例神经内分泌肿瘤患者数据。采用限制平均生存时间与Kaplan-Meier生存估计法，计算各解剖部位神经内分泌肿瘤患者中男性和女性的60个月生存率，并据此计算60个月限制平均生存时间下的女性生存优势值。结果：NCRAS与SEER数据库中的女性生存优势值具有相似性，其中肺部和胃部神经内分泌肿瘤的女性生存优势最为显著。结论：SEER数据库数据证实了NCRAS已发表的研究发现，但女性生存优势的具体机制仍有待阐明。
肿瘤(癌症)患者之家